Printer Friendly

Complications Following Radiofrequency Ablation of Benign Thyroid Nodules: A Systematic Review.

Byline: Jin-Fen. Wang, Tao. Wu, Kun-Peng. Hu, Wen. Xu, Bo-Wen. Zheng, Ge. Tong, Zhi-Cheng. Yao, Bo. Liu, Jie. Ren

Objective: This systematic review examined whether radiofrequency ablation (RFA) is a safe treatment modality for benign thyroid nodules (BTNs). Data Sources: PubMed, Embase, and the Cochrane Library database were searched for articles that (a) targeted human beings and (b) had a study population with BTNs that were confirmed by fine-needle aspiration cytology and/or core needle biopsy. Study Selection: Thirty-two studies relating to 3409 patients were included in this systematic review. Results: Based on literatures, no deaths were associated with the procedure, serious complications were rare, and RFA appears to be a safe and well-tolerated treatment modality. However, a broad spectrum of complications offers insights into some undesirable complications, such as track needle seeding and Horner syndrome. Conclusions: RFA appears to be a safe and well-tolerated treatment modality for BTNs. More research is needed to characterize the complications of RFA for thyroid nodules.


Thyroid nodules are extremely common in the general population.[sup][1] Some patients with benign thyroid nodules (BTNs) may require treatment due to nodule-related clinical problems.[sup][2],[3],[4] With respect to the common treatment methods for BTNs, surgery has some drawbacks, and levothyroxine suppressive therapy has the potential to cause harm that outweighs the benefit for most patients [sup][2],[3],[5],[6],[7] Since the first report of radiofrequency ablation (RFA) for the treatment of BTNs in 2006,[sup][8] this minimally invasive technique has been considered to be a safe and effective alternative to surgery. Studies available in literature reported that the nodule volume reduction after RFA ranged from 47.7% to 96.9% and that the symptom grading score improvement ranged from 2.1–6.1 to 0.2–2.5 (10-cm visual analog scale).[sup][9],[10],[11],[12],[13] Technically, an ultrasound (US)-guided RF electrode is usually inserted from the thyroid isthmus to the lateral aspect of a targeted nodule, and the heat generated from high-frequency alternating electric current leads to irreversible damage of the tumor tissue around the electrode. In contrast to the fixed electrode that is used to treat liver tumors, the moving shot technique that was proposed by Baek et al. is a core technique that was designed to optimize thyroid ablation and avoid damage to the surrounding critical structures.[sup][14]

Nevertheless, RFA is technically challenging and requires extensive experience. It is extremely important for the operator to understand all possible complications and related preventive measures. However, a systematic record of these factors does not exist. Therefore, we aimed to collect and summarize all reported postablation adverse events. In this review, the likelihood, severity, clinical features, and prognosis of various adverse events are presented. Possible causes and measures used for prevention and treatment are discussed. This systematic review, while subject to some biases, has the advantage of representing experiences from large centers as well as individual cases from small centers, including centers in under-resourced countries.


A literature search of the electronic databases of PubMed, Embase, and the Cochrane Library was performed in December 2016, without restricting the region, publication type, or language. The following keywords were used to search for articles: radiofrequency, ablation/radio-frequency, ablation/radiofrequency, catheter ablation, and thyroid nodule/thyroid. A search for a relevant meta-analysis or systematic review in both electronic databases retrieved no results. After, we supplemented the search with manual searches of the reference lists of all retrieved studies, review articles, and conference abstracts. Upon retrieval of potentially eligible studies, the full-texts were evaluated for eligibility. Except for animal experiments and literature reviews, this article included all studies that described the complications of RFA for BTNs. Only those patients whose diagnosis was confirmed by fine-needle aspiration (FNA), cytology, and/or core needle biopsy were recruited. When multiple reports describing the same population were published, the most recent or most complete report was used. A total of 32 studies relating to 3409 patients were included in the study. The literature search and screening process for this systematic review are summarized in [Figure 1] and Supplementary 1 [SUPPORTING:1], respectively.{Figure 1}

All of the 32 included studies in which complications were reported are represented in [Table 1]. The likelihood and severity, related preventive measures, and therapy reported for each complication are presented in [Table 2]. A synopsis of the relevant patient preparation, procedures, and follow-up RFA is provided in Supplementary 2 [SUPPORTING:2].{Table 1}{Table 2}


Voice change/hoarseness

As a serious complication of RFA, voice change/hoarseness can be found during the procedure or immediately after ablation. Voice change is usually transient, and most patients recover spontaneously within 3 months without special treatments.[sup][8],[19],[21],[26],[41],[42],[43],[46] Prednisone may be useful for reducing the recovery period.[sup][22] One patient experienced permanent right paramedian vocal cord palsy with inspiratory stridor but without dysphonia.[sup][26] Another patient who complained of dysphonia postablation demonstrated ipsilateral vocal cord palsy upon laryngoscopic evaluation, and this symptom lasted for approximately 1 month. However, this patient was then lost to follow-up.[sup][8] Despite the rarity of permanent voice changes following RFA for BTNs, a higher incidence has been reported in patients with recurrent thyroid cancers after RFA.[sup][39]

Four patients with voice changes were diagnosed with recurrent laryngeal nerve injury by laryngoscopic evaluation.[sup][10],[12] The proposed mechanisms included RFA-induced thermal injury of the recurrent laryngeal nerve or vagus nerve, lidocaine injection leading to transient voice change, stretching of the nerve over a hematoma, posthemorrhage inflammation, and fibrosis around the nerve.[sup][19],[39]

It is crucial for surgeons to understand complicated neck anatomy and assess the location and variation of the relevant nerves (recurrent laryngeal nerve and vagus nerve) before RFA. In general, the recurrent laryngeal nerve is located in the tracheoesophageal grooves, and the vagus nerve is located between the carotid artery and internal jugular vein, but variations of the vagus nerve and a bulging large thyroid nodule may change the location of the vagus nerve, positioning it closer to the thyroid nodule.[sup][44],[48],[49] To avoid nerve injury, several methods are recommended, including the “transisthmic approach method,” the “moving-shot technique,” hydrodissection between the nodule and dangerous triangle, the maintenance of a minimal distance of more than 3 mm between the RF electrode and nerves, and undertreating the ablation units adjacent to the recurrent laryngeal nerve.[sup][29],[44],[47] Meanwhile, the patient should be encouraged to communicate with the surgeon intermittently throughout the procedure to assess whether any voice changes or hoarseness occur.[sup][44]

Brachial plexus nerve injury

Although puncture of the brachial plexus nerve is an unlikely complication post-RFA given the deep location of the nerve, direct evidence for this complication was reported in one case.[sup][8],[19] The patient complained of numbness and decreased sensation in the fourth and fifth fingers of the left hand and gradually recovered over the next 2 months. Penetration of the electrode outside the thyroid gland during RFA due to visual disturbance caused by echogenic bubbles may be the cause of this complication. Thus, the entire electrode should always be visualized by real-time US images during the RFA procedure.

Horner syndrome

Horner syndrome has been reported immediately following RFA, with ocular discomfort and redness of the conjunctiva as symptoms. The patient subsequently developed clinical features of Horner syndrome, such as ptosis, miosis, and anhidrosis of the face. Without further management, the patient improved slightly after 6 months, but the syndrome persisted.[sup][39]

In the patient who developed Horner syndrome, the nodule that was treated with RFA was close to the middle cervical sympathetic ganglion (mCSG). Thermal injury or hematoma compression of the mCSG may explain this complication. The location of the mCSG is usually at the lower level of the thyroid gland and lateral to the common carotid artery, which is visible in 41% of US images.[sup][49] However, the authors emphasized that caution should be used when differentiating between the mCSG and various surrounding structures, such as the lymph nodes, longus capitis muscle, and thyroid incidentaloma, on US examination.[sup][50]

Nodule rupture

Although post-RFA nodule rupture is rare as a serious complication, 14 cases were reported in the included articles.[sup][16],[27],[29],[39] The definition of nodule rupture post-RFA of the thyroid gland is the breakdown of the thyroid capsule and a leak of the fluid from intrathyroidal lesions toward extrathyroidal lesions.

The patients usually reported sudden neck swelling and pain at the RFA site between 9 days and 5 months after RFA.[sup][16],[19],[27] Sonography and/or computed tomography (CT) could help diagnose this complication, which is visualized as the breakdown of the thyroid capsule and the formation of a new mass located between intra- and extra-thyroidal lesions at the RF site.[sup][16] The lesions ultimately disappeared in seven patients without medication or invasive procedures. Two patients were treated with antibiotics, and the lesions gradually regressed. However, three patients ultimately underwent incision and drainage due to worsening clinical signs.[sup][16] One patient with nodule rupture who underwent unilateral lobectomy was also described. That patient presented aggravated pain with neck skin redness several days after the diagnosis of the rupture due to cellulitis of the anterior neck and abscess formation.[sup][16]

The main proposed mechanism of nodule rupture may be delayed bleeding caused by microvessel leakage within the nodule, leading to delayed volume expansion and rupture. This mechanism was proposed because some patients demonstrated new hyperechoic or high-attenuation portions on sonography or CT, which suggested intratumoral bleeding, and semisolid bloody material without bacterial growth was aspirated. Other causes of nodule rupture may include tearing of the tumor wall and thyroid capsule at a weak point, post-RFA massage, or strong movement of the neck.[sup][39],[16]

No specific nodule characteristics were predictive of nodule rupture. However, the following risk factors have been proposed: BTNs near the anterior thyroid capsule, in which the neck space on the anterior surface of the thyroid may not be as tight as on the other sides; large and mixed component nodules consisting of highly heterogenetic tissue, which may require more RF power through the use of multiple ablations, a higher maximum RFA power, and a longer ablation time.[sup][16]

There is no established management protocol for nodule rupture of BTNs post-RFA. Conservative treatment rather than additional invasive procedures is recommended as the first step, as the absence of bacterial growth within the lesion has been confirmed in several cases. Anti-inflammatory and analgesics drugs can be used carefully if necessary. However, invasive management, such as drainage, excision, or even surgery, should be suggested if the symptoms are aggravated, particularly if the symptoms suggest delayed abscess formation.[sup][16]

Needle track seeding

Needle track seeding is a severe complication. However, this complication is rare after RFA of all types of organs, even after RFA and FNA of thyroid carcinoma.[sup][51],[52],[53],[54] Two cases of needle track seeding were described after RFA for thyroid nodules that were proven to be BTNs by FNA.[sup][25],[37]

In one patient with a thyroid nodule that was revealed to be nodular hyperplasia versus a follicular neoplasm by FNA before the procedure, multiple new masses were found in the anterior muscle and both thyroid lobes in 2 years post-second RFA. The pathological result of the RFA-treated nodule was papillary thyroid carcinoma with central lymph node metastasis after total thyroidectomy.[sup][25] In another case with a colloid nodular hyperplasia revealed by FNA before ablation, a new extrathyroid suprafascial mass was found on US 30-month post-RFA; surgery and pathology showed a follicular carcinoma with a minority component of papillary carcinoma.[sup][37]

Lee et al .[sup][25] summarized three possibilities: incidental malignant potential of the BTN, transformation of new malignant cells by RFA, and sampling error of FNA. BTNs confirmed through FNA have been described in approximately 2.5% of cases with an actual risk of malignancy in surgically excised nodules.

At least two separate US-guided FNA or core needle biopsy procedures are crucial before RFA to characterize BTNs. Caution should be used with thyroid nodules with malignant US features, even if cytology yields benign results.[sup][22],[44] During follow-up, increased or stable nodule volume should be reassessed carefully to avoid unsatisfactory treatment results, and yearly follow-up is recommended for 5 years.[sup][22],[44]


In general, RFA has a minimal influence on thyroid function. Three cases of post-RFA hypothyroidism have been described.[sup][14],[19],[32] One case with transient hypothyroidism presented an increased serum thyroid stimulating hormone (TSH) concentration without any symptoms immediately post-RFA and then recovered spontaneously by the 1-year follow-up visit.[sup][39] Another patient with elevated anti-thyroglobulin antibody (TGAb) levels before ablation developed subclinical hypothyroidism (TSH 5.6 mU/ml) by the 12-month follow-up and aggravated hypothyroidism by the 15-month follow-up (TSH 36.7 mU/ml).[sup][14] Moreover, permanent hypothyroidism was detected 6-month post-RFA, manifesting as gradual neck bulging and diffuse enlarged thyroid without nodules upon US examination, as well as a reduced serum-free thyroxine (FT4) concentration and an increased serum TSH concentration. It is interesting that the last patient also showed persistent elevation of serum anti- thyroid peroxidase antibody (TPOAb) before and after RFA.[sup][19]

The cause of hypothyroidism after RFA of thyroid nodules is unclear, but it is worth noting that two cases of post-RFA hypothyroidism showed increased serum thyroid antibodies (anti-TPOAb and anti-TGAb) before the procedure. Patients who developed hypothyroidism after ethanol ablation and laser ablation also showed persistent elevation of serum thyroid antibodies before and after RFA.[sup][55],[56] Although some authors have suggested that the probable cause of hypothyroidism is a progression of autoimmune thyroiditis associated with preexisting thyroid antibodies,[sup][57],[58] thyroid antibodies should be monitored in all patients during follow-up to study thyroid autoimmunity after ablation techniques that expose thyroid antigens.

Although the risk of hypothyroidism is very low, it is necessary to inform patients with elevated serum thyroid antibodies before ablation about the possibility of hypothyroidism after the procedure.

Transient thyrotoxicosis

Thyrotoxicosis was indicated by a thyroid hormone increase and a TSH decrease. In all studies, one case of late-onset, painless thyroiditis with transient thyrotoxicosis occurred 3 months post-RFA.[sup][22] The patient recovered spontaneously within 30 days without developing hypothyroidism.

As reported by Kobayashi et al .,[sup][55] thyroiditis with thyrotoxicosis after needle aspiration of a thyroid cyst is regarded to be an inflammatory process. The procedure triggers the release of thyroid hormones. The complication may be caused post-RFA through a mechanism similar to that reported for postaspiration thyrotoxicosis. Postoperative transient abnormal thyroid function tests should be considered a normal response to the procedure.

Pseudocystic transformation (colliquation)

One case of pseudocystic transformation (colliquation) occurred 3 weeks after the RFA procedure, manifesting as pain and sudden swelling, which is similar to nodule rupture. An additional course of corticosteroids (oral methyl prednisone: 16 mg for the 1[sup]st week, 8 mg for the 2[sup]nd week, and 4 mg for the 3[sup]rd week) was administered, but the outcome of the patient was not mentioned in the article.[sup][27]

US could be useful for diagnosing pseudocystic transformation, but we should note that the normal sonographic appearance of thyroid nodules post-PFA, such as marked hypoechogenicity, heterogeneity, and irregular margins, may be misleading.

Pain/sensation of heat

Pain, with an incidence rate ranging from 2.6% to 17.5%, is the most common complaint during the procedure and is generally accompanied by a sensation of heat.[sup][20],[23],[30],[31],[33],[34],[35],[45]

The general location of pain was the neck, occasionally radiating around toward the head, gonial angle, ear, shoulder, or teeth.[sup][18],[36],[59] Most patients experienced sustainably mild–to-moderate pain, while a few patients suffered intense intraoperative pain (visual analog score> 5 or requiring medication).[sup][13],[27] Overall, only one patient was reported to be incompletely treated due to severe chest pain in all studies.[sup][26]

The most probable reason for pain is parenchymal edema and thyroid capsule thermal damage.[sup][27] Other factors associated with the probability and severity of pain include monopolar RFA, location of the BTNs (especially adjacent to vulnerable vital structures), needle size, lack of expertise, and vigorous handing of the needle.

Although this complication is frequently reported during RFA, it is usually self-limited, decreasing or disappearing rapidly when the RF power output is reduced or RFA is stopped. Local anesthesia is routinely recommended for pain prevention during needle insertion and electrode positioning.[sup][15],[44],[60] If the pain lasts days or cannot be tolerated, oral analgesics (acetaminophen or paracetamol) can be used to control this symptom easily for no more than 3 days.[sup][17],[19],[22],[31] An ice pack can be used at the puncture site to relieve local post-RFA pain and discomfort, despite the absence of direct evidence. Painkillers and sedatives for pain relief during the ablation should not be recommended because such medications affect the early detection of complications.[sup][10]


The reported incidence of hematoma in the included studies was relatively low. These studies reported perithyroidal, subcapsular, and intranodular hemorrhage.[sup][12],[19],[27],[33],[40],[46]

Small hemorrhages/hematomas are usually asymptomatic. Most hematomas can be detected by real-time US. Intranodular hemorrhage during needle insertion appeared as a rapidly expanding hypo/anechoic signal within the nodular tissue, resulting in gradual enlargement. Perithyroidal hemorrhage was found immediately after the procedure as a hypoechoic thin layer surrounding the thyroid lobe or intrathyroid. Extensive neck bruising may appear 5–10 days after RFA, but this symptom will disappear in approximately 3–4 weeks.[sup][27]

For solid BTNs, the rich blood supply of the BTN contributes to the susceptibility to post-RFA hemorrhage. The intranodular arteriovenous shunts in these BTNs, which divert blood to the weakened veins under high pressure, may also be associated with hemorrhage. For cystic or complex nodules, an additional mechanism for hemorrhage soon after fluid aspiration is the sudden reduction of intranodular pressure due to fluid evacuation.[sup][61]

Most hematomas can be prevented or controlled. Patients should be informed to stop taking drugs associated with hemorrhage risk for a period before RFA.[sup][44] During RFA, hemorrhage is prevented by swift needle-electrode insertion and heat administration, such as avoiding large blood vessels and blocking the supplying artery. When a hematoma is found by US, mild pressure should be applied to the neck for several minutes. In most cases, this complication completely disappeared within 1 month.[sup][19],[27],[62] Although no patients with hemorrhage/hematoma needed further hospital or surgical treatment in any study,[sup][63],[64] uncontrolled hemorrhage and massive hematoma can induce acute upper airway obstruction and may develop rapidly.[sup][65],[66],[67] Therefore, close examination and follow-up are necessary during and after the procedure.


Twelve patients experienced vomiting/nausea post-RFA, but no patients complained of vomiting or nausea during ablation.[sup][12],[19] Postoperative nausea and vomiting is a common complication after thyroidectomy, which can reach 70–80% when no prophylactic antiemetic therapy is administered.[sup][68],[69],[70] The most possible cause is excessive extension of the neck, which can cause an imbalance of cerebral blood flow, resulting in central nausea and vomiting.[sup][71] Vagus nerve stimulation during the neck surgery may be responsible.[sup][70],[72] In addition, the following factors may play an important role: female gender, age, nonsmoker, and history of nausea and vomiting.[sup][73] Treatment with antiemetics can improve this symptom within 1–2 days.[sup][19] In addition, a supplement with sufficient energy is needed for patients with severe vomiting post-RFA.

Skin burn

Six cases of skin burn at the puncture site post-RFA were reported. Five of these cases involved first-grade skin burns, which presented with skin color changes and mild pain and discomfort. The patients recovered within 10 days without specific management.[sup][8],[19],[24] However, another case of serious full-thickness burn post-RFA was caused by the use of an active needle tip in proximity to the skin.[sup][38] The patient received topical gentamicin sulfate and hyaluronic acid on the skin burn for the 1[sup]st week, activated charcoal cloth with silver for the 2[sup]nd week, and a collagen wound dressing for another 2 weeks after surgical debridement of the wound. The skin burn recovered one month later.

Minimally invasive ablative therapy requires a good appearance; therefore, more attention should be paid to this complication. The physician must be careful when the active needle tips move close to the skin. Injecting cold water into the subcutaneous layers under the puncture site may be helpful for increasing the distance between the skin and nodule. It is also helpful to use an ice bag during the procedure to prevent skin burns.


Post-RFA fever has not been adequately studied, and only a few cases have been reported.[sup][15],[19],[27],[28] Post-RFA acute reaction of the ablation zone may play a role in the pathogenesis of this complication. Mild–to-moderate fevers of up to 38.0[degrees]C or 38.5[degrees]C were recorded. The fever regressed spontaneously within 3 days post-RFA and did not require any additional therapy.


There is inconsistency in the reported incidence of swelling during or after RFA in different studies due to the use of different definitions.[sup][10],[19],[27],[35],[39]

Some authors have suggested that a minimal amount of acute transient swelling of the thyroid nodules and the surrounding thyroid parenchyma immediately after RFA, with no symptoms and no additional treatment, are inevitable. Those authors considered such swelling to be neither a complication nor a side effect.[sup][39] However, swelling with pressure symptoms but without airway obstruction due to an increase in nodule volume and the surrounding thyroid parenchyma was also reported in seven patients.[sup][10],[27] Three of these seven patients required a single administration of 1.5 mg of betamethasone to control edema, and the remaining cases resolved spontaneously within 1–7 days.[sup][10],[27]

Beyond edema of the thyroid nodule, one case of painful swelling of the skin tissue was reported postablation. This complication disappeared completely in 12 days with oral anti-inflammatory treatment.[sup][35]

Acute swelling may sound frightening, but because this symptom is self-limiting and transient, awareness helps avoid unnecessary interventions.

Diffuse glandular hemorrhage

Only one case of diffuse glandular hemorrhage during RFA of a solid BTN was reported, with the symptoms of severe pain and anterior neck swelling, leading to discontinuation of the procedure.[sup][17] This patient took oral analgesics for 3 days, and the diffuse glandular hemorrhage disappeared on follow-up US at 1-month post-RFA. The author made no comment about the pathogenesis of this case.


Due to its anatomic location, injury of the trachea could be a complication post-RFA, but no relevant reports were found. Only a few cases with cough have been reported.[sup][19],[27],[39] Coughing is induced by the movement of the electrode needle close to the trachea and can be managed by pulling back and stopping the RFA procedure. Coughing usually lasted 10–40 s, without any symptoms associated with heat injury to the trachea detected during follow-up.

Vasovagal reaction

Vasovagal reactions occurred with bradycardia, hypotension, vomiting, difficulty breathing, and defecation. Nineteen cases have been reported.[sup][19],[27],[39] These reactions may be caused by vagus nerve stimulation if the nodule is adjacent to the common carotid and the internal jugular vein. The symptoms usually last a few minutes, but they may make patients nervous. Calming the patient down, elevating the patient's legs, and stopping the ablation until spontaneous recovery is achieved are advised. This type of management will not influence the subsequent RFA.[sup][27]


Increases in blood pressure were detected during the procedure in twelve patients. Four patients were treated with medication due to large blood pressure increases (more than 40 mmHg), while the remaining eight patients were observed and treated without medication.[sup][39] Although all patients who received medication for hypertension during RFA had underlying hypertension, possible causes of blood pressure elevation are pain or the release of thyroid hormone during the ablation. Thus, to rapidly identify abnormal changes, it is important to monitor the patient's blood pressure during the ablation.

Muscle twitching

Only one patient suffered from transient muscle twitching during the ablation procedure, which was presumably caused by lidocaine toxicity.[sup][39] The permitted maximal dose of lidocaine is 4.5 mg/kg, up to a total of 300 mg (15 ml). The symptoms of lidocaine toxicity include mental changes, muscle twitching, tremors, and seizures.[sup][74] Thus, the surgical team should prevent lidocaine overdose and consider the possibility of lidocaine toxicity.


There are four limitations to this study that are worth addressing. First, the criteria used to define complications and the time sequences were different as the patients came from different centers with their own criteria. Only one retrospective study defined these terms according to the standardized terminology for image-guided tumor ablation from the Society of Interventional Radiology.[sup][39] Second, post-RFA thyroid complications are rarely recorded systematically. Even in large thyroid RFA series, complications were either not reported or were mentioned to be limited. Such results could reflect the inconsistent definitions of complications, and teams who perform RFA with undesirable consequences may be unwilling to publish their results. Moreover, case reports or case series of minor or previously reported complications are not typically accepted by journals. Third, the absence of randomized controlled trials and the availability of only two retrospective studies designed to record thyroid RFA complications as the primary aim prevented a meta-analysis from being performed. Moreover, a majority of the articles had an observational design, which precluded the ability to comment on the precise risks and causes of complications.

Although the conclusions of this review cannot serve as conclusive answers, we believe that this review of the available data could contribute to the knowledge of all reported complications of RFA, even rare or challenging complications, such as needle track seeding.


As a minimally invasive treatment modality for BTNs, RFA is safe and extremely well tolerated. None of the reported patients experienced any life-threatening complications related to RFA, and the rate of serious complications was low. However, this broad spectrum of complications offers insights into the essential nature of neck anatomy, physicians' experiences with US-guided interventional procedures, preprocedural evaluations, and preventive measures.

Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website.

Financial support and sponsorship

This study was funded by grant Sun Yat-Sen University Clinical Research 5010 Program (No. 2016016).

Conflicts of interest

There are no conflicts of interest.


1. Sharen G, Zhang B, Zhao R, Sun J, Gai X, Lou H. Retrospective epidemiological study of thyroid nodules by ultrasound in asymptomatic subjects. Chin Med J 2014;127:1661-5. doi: 10.3760cma.j.issn.0366-6999.20132469.

2. Gharib H, Papini E, Garber JR, Duick DS, Harrell RM, Hegedus L, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medicai Endocrinologi Medical Guidelines for clinical practice for the diagnosis and management of thyroid nodules-2016 update. Endocr Pract 2016;22:622-39. doi: 10.4158/

3. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133. doi: 10.1089/thy.2015.0020.

4. Huan Q, Wang K, Lou F, Zhang L, Huang Q, Han Y, et al. Epidemiological characteristics of thyroid nodules and risk factors for malignant nodules: A retrospective study from 6,304 surgical cases. Chin Med J 2014;127:2286-92. doi: 10.3760cma.j.issn.0366-6999.20132469.

5. Gharib H. Changing trends in thyroid practice: Understanding nodular thyroid disease. Endocr Pract 2004;10:31-9. doi: 10.4158/ep.10.1.31.

6. Jeannon JP, Orabi AA, Bruch GA, Abdalsalam HA, Simo R. Diagnosis of recurrent laryngeal nerve palsy after thyroidectomy: A systematic review. Int J Clin Pract 2009;63:624-9. doi: 10.1111/j.1742-1241.2008.01875.x.

7. Linos D, Economopoulos KP, Kiriakopoulos A, Linos E, Petralias A. Scar perceptions after thyroid and parathyroid surgery: Comparison of minimal and conventional approaches. Surgery 2013;153:400-7. doi: 10.1016/j.surg.2012.08.008.

8. Kim YS, Rhim H, Tae K, Park DW, Kim ST. Radiofrequency ablation of benign cold thyroid nodules: Initial clinical experience. Thyroid 2006;16:361-7. doi: 16:361-7. 10.1089/thy.2006.16.361.

9. Lee JH, Kim YS, Lee D, Choi H, Yoo H, Baek JH. Radiofrequency ablation (RFA) of benign thyroid nodules in patients with incompletely resolved clinical problems after ethanol ablation (EA). World J Surg 2010;34:1488-93. doi: 10.1007/s00268-010-0565-6.

10. Deandrea M, Limone P, Basso E, Mormile A, Ragazzoni F, Gamarra E, et al. US-guided percutaneous radiofrequency thermal ablation for the treatment of solid benign hyperfunctioning or compressive thyroid nodules. Ultrasound Med Biol 2008;34:784-91. doi: 10.1016/j.ultrasmedbio.2007.10.018.

11. Sung JY, Kim YS, Choi H, Lee JH, Baek JH. Optimum first-line treatment technique for benign cystic thyroid nodules: Ethanol ablation or radiofrequency ablation? AJR Am J Roentgenol 2011;196:W210-4. doi: 10.2214/ajr.10.5172.

12. Lim HK, Lee JH, Ha EJ, Sung JY, Kim JK, Baek JH. Radiofrequency ablation of benign non-functioning thyroid nodules: 4-year follow-up results for 111 patients. Eur Radiol 2013;23:1044-9. doi: 10.1007/s00330-012-2671-3.

13. Baek JH, Ha EJ, Choi YJ, Sung JY, Kim JK, Shong YK. Radiofrequency versus ethanol ablation for treating predominantly cystic thyroid nodules: A randomized clinical trial. Korean J Radiol 2015;16:1332-40. doi: 10.3348/kjr.2015.16.6.1332.

14. Baek JH, Moon WJ, Kim YS, Lee JH, Lee D. Radiofrequency ablation for the treatment of autonomously functioning thyroid nodules. World J Surg 2009;33:1971-7. doi: 10.1007/s00268-009-0130-3.

15. Spiezia S, Garberoglio R, Milone F, Ramundo V, Caiazzo C, Assanti AP, et al. Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation. Thyroid 2009;19:219-25. doi: 10.1089/thy.2008.0202.

16. Shin JH, Jung SL, Baek JH, Kim JH. Rupture of benign thyroid tumors after radio-frequency ablation. AJNR Am J Neuroradiol 2011;32:2165-9. doi: 10.3174/ajnr.A2661.

17. Kim DW. Sonography-guided ethanol ablation of a remnant solid component after radio-frequency ablation of benign solid thyroid nodules: A preliminary study. AJNR Am J Neuroradiol 2012;33:1139-43. doi: 10.3174/ajnr.A2904.

18. Faggiano A, Ramundo V, Assanti AP, Fonderico F, Macchia PE, Misso C, et al. Thyroid nodules treated with percutaneous radiofrequency thermal ablation: A comparative study. J Clin Endocrinol Metab 2012;97:4439-45. doi: 10.1210/jc.2012-2251.

19. Baek JH, Lee JH, Sung JY, Bae JI, Kim KT, Sim J, et al. Complications encountered in the treatment of benign thyroid nodules with US-guided radiofrequency ablation: A multicenter study. Radiology 2012;262:335-42. doi: 10.1148/radiol.11110416.

20. Sung JY, Baek JH, Kim KS, Lee D, Yoo H, Kim JK, et al. Single-session treatment of benign cystic thyroid nodules with ethanol versus radiofrequency ablation: A prospective randomized study. Radiology 2013;269:293-300. doi: 10.1148/radiol.13122134.

21. Sui Y, Wu FL, Hu J, Liu LY. Method and short term efficacy of ultrasound-guided radiofrequency ablation of thyroid benign nodules. Chin J Med Imaging Technol 2013;29:706-9. doi: 10.13929/j.1003-3289.2013.05.027.

22. Bernardi S, Dobrinja C, Fabris B, Bazzocchi G, Sabato N, Ulcigrai V, et al. Radiofrequency ablation compared to surgery for the treatment of benign thyroid nodules. Int J Endocrinol 2014;2014:934595. doi: 10.1155/2014/934595.

23. Yoon HM, Baek JH, Lee JH, Ha EJ, Kim JK, Yoon JH, et al. Combination therapy consisting of ethanol and radiofrequency ablation for predominantly cystic thyroid nodules. AJNR Am J Neuroradiol 2014;35:582-6. doi: 10.3174/ajnr.A3701.

24. Turtulici G, Orlandi D, Corazza A, Sartoris R, Derchi LE, Silvestri E, et al. Percutaneous radiofrequency ablation of benign thyroid nodules assisted by a virtual needle tracking system. Ultrasound Med Biol 2014;40:1447-52. doi: 10.1016/j.ultrasmedbio.2014.02.017.

25. Lee CU, Kim SJ, Sung JY, Park SH, Chong S, Baek JH. Needle track tumor seeding after radiofrequency ablation of a thyroid tumor. Jpn J Radiol 2014;32:661-3. doi: 10.1007/s11604-014-0350-9.

26. Cesareo R, Pasqualini V, Simeoni C, Sacchi M, Saralli E, Campagna G, et al. Prospective study of effectiveness of ultrasound-guided radiofrequency ablation versus control group in patients affected by benign thyroid nodules. J Clin Endocrinol Metab 2015;100:460-6. doi: 10.1210/jc.2014-2186.

27. Valcavi R, Tsamatropoulos P. Health-related quality of life after percutaneous radiofrequency ablation of cold, solid, benign thyroid nodules: A 2-year follow-up study in 40 patients. Endocr Pract 2015;21:887-96. doi: 10.4158/ep15676.or.

28. Deandrea M, Sung JY, Limone P, Mormile A, Garino F, Ragazzoni F, et al. Efficacy and safety of radiofrequency ablation versus observation for nonfunctioning benign thyroid nodules: A randomized controlled international collaborative trial. Thyroid 2015;25:890-6. doi: 10.1089/thy.2015.0133.

29. Che Y, Jin S, Shi C, Wang L, Zhang X, Li Y, et al. Treatment of benign thyroid nodules: Comparison of surgery with radiofrequency ablation. AJNR Am J Neuroradiol 2015;36:1321-5. doi: 10.3174/ajnr.A4276.

30. Sung JY, Baek JH, Jung SL, Kim JH, Kim KS, Lee D, et al. Radiofrequency ablation for autonomously functioning thyroid nodules: A multicenter study. Thyroid 2015;25:112-7. doi: 10.1089/thy.2014.0100.

31. Ugurlu MU, Uprak K, Akpinar IN, Attaallah W, Yegen C, Gulluoglu BM. Radiofrequency ablation of benign symptomatic thyroid nodules: Prospective safety and efficacy study. World J Surg 2015;39:961-8. doi: 10.1007/s00268-014-2896-1.

32. Kohlhase KD, Korkusuz Y, Groner D, Erbelding C, Happel C, Luboldt W, et al. Bipolar radiofrequency ablation of benign thyroid nodules using a multiple overlapping shot technique in a 3-month follow-up. Int J Hyperthermia 2016;32:511-6. doi: 10.3109/02656736.2016.1149234.

33. Korkusuz Y, Erbelding C, Kohlhase K, Luboldt W, Happel C, Grunwald F. Bipolar radiofrequency ablation of benign symptomatic thyroid nodules: Initial experience. Rofo 2016;188:671-5. doi: 10.1055/s-0041-110137.

34. Ahn HS, Kim SJ, Park SH, Seo M. Radiofrequency ablation of benign thyroid nodules: Evaluation of the treatment efficacy using ultrasonography. Ultrasonography 2016;35:244-52. doi: 10.14366/usg.15083.

35. Aysan E, Idiz UO, Akbulut H, Elmas L. Single-session radiofrequency ablation on benign thyroid nodules: A prospective single center study: Radiofrequency ablation on thyroid. Langenbecks Arch Surg 2016;401:357-63. doi: 10.1007/s00423-016-1408-1.

36. Li XL, Xu HX, Lu F, Yue WW, Sun LP, Bo XW, et al. Treatment efficacy and safety of ultrasound-guided percutaneous bipolar radiofrequency ablation for benign thyroid nodules. Br J Radiol 2016;89:20150858. doi: 10.1259/bjr.20150858.

37. Oddo S, Spina B, Vellone VG, Giusti M. A case of thyroid cancer on the track of the radiofrequency electrode 30 months after percutaneous ablation. J Endocrinol Invest 2017;40:101-2. doi: 10.1007/s40618-016-0527-4.

38. Bernardi S, Lanzilotti V, Papa G, Panizzo N, Dobrinja C, Fabris B, et al. Full-thickness skin burn caused by radiofrequency ablation of a benign thyroid nodule. Thyroid 2016;26:183-4. doi: 10.1089/thy.2015.0453.

39. Kim C, Lee JH, Choi YJ, Kim WB, Sung TY, Baek JH, et al. Complications encountered in ultrasonography-guided radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers. Eur Radiol 2016; Epub ahead of print. doi: 10.1007/s00330-016-4690-y.

40. Zhao CK, Xu HX, Lu F, Sun LP, He YP, Guo LH, et al . Factors associated with initial incomplete ablation for benign thyroid nodules after radiofrequency ablation:First results of CEUS evaluation. Clin Hemorheol Microcirc 2017;65:393-405. doi: 10.3233/ch-16208.

41. Bernardi S, Stacul F, Michelli A, Giudici F, Zuolo G, de Manzini N, et al . 12-month efficacy of a single radiofrequency ablation on autonomously functioning thyroid nodules. Endocrine 2016; Epub ahead of print. doi: 10.1007/s12020-016-1174-4.

42. Yue WW, Wang SR, Lu F, Sun LP, Guo LH, Zhang YL, et al. Radiofrequency ablation vs. microwave ablation for patients with benign thyroid nodules: A propensity score matching study. Endocrine 2017;55:485-95. doi: 10.1007/s12020-016-1173-5.

43. Zhang Y, Zhang MW, Fan XX. Ultrasound-guided radiofrequency ablation for the treatment of benign thyroid nodules: Preliminary results in 27 cases (in Chinese). J Intervent Radiol 2016;25:136-40. doi: 10.3969j.issn.1008-794X.2016.02.011.

44. Na DG, Lee JH, Jung SL, Kim JH, Sung JY, Shin JH, et al. Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: Consensus statement and recommendations. Korean J Radiol 2012;13:117-25. doi: 10.3348/kjr.2012.13.2.117.

45. Spiezia S, Garberoglio R, Di Somma C, Deandrea M, Basso E, Limone PP, et al. Efficacy and safety of radiofrequency thermal ablation in the treatment of thyroid nodules with pressure symptoms in elderly patients. J Am Geriatr Soc 2007;55:1478-9. doi: 10.1111/j.1532-5415.2007.01306.x.

46. Jeong WK, Baek JH, Rhim H, Kim YS, Kwak MS, Jeong HJ, et al. Radiofrequency ablation of benign thyroid nodules: Safety and imaging follow-up in 236 patients. Eur Radiol 2008;18:1244-50. doi: 10.1007/s00330-008-0880-6.

47. Ha EJ, Baek JH, Lee JH. Moving-shot versus fixed electrode techniques for radiofrequency ablation: Comparison in an ex-vivo bovine liver tissue model. Korean J Radiol 2014;15:836-43. doi: 10.3348/kjr.2014.15.6.836.

48. Ha EJ, Baek JH, Lee JH, Kim JK, Shong YK. Clinical significance of vagus nerve variation in radiofrequency ablation of thyroid nodules. Eur Radiol 2011;21:2151-7. doi: 10.1007/s00330-011-2167-6.

49. Ha EJ, Baek JH, Lee JH. Ultrasonography-based thyroidal and perithyroidal anatomy and its clinical significance. Korean J Radiol 2015;16:749-66. doi: 10.3348/kjr.2015.16.4.749.

50. Shin JE, Baek JH, Ha EJ, Choi YJ, Choi WJ, Lee JH. Ultrasound features of middle cervical sympathetic ganglion. Clin J Pain 2015;31:909-13. doi: 10.1097/ajp.0000000000000184.

51. Howenstein MJ, Sato KT. Complications of radiofrequency ablation of hepatic, pulmonary, and renal neoplasms. Semin Intervent Radiol 2010;27:285-95. doi: 10.1055/s-0030-1261787.

52. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. Needle tract implantation of papillary thyroid carcinoma after fine-needle aspiration biopsy. World J Surg 2005;29:1544-9. doi: 10.1007/s00268-005-0086-x.

53. Polyzos SA, Anastasilakis AD. A systematic review of cases reporting needle tract seeding following thyroid fine needle biopsy. World J Surg 2010;34:844-51. doi: 10.1007/s00268-009-0362-2.

54. Suh CH, Baek JH, Choi YJ, Lee JH. Efficacy and safety of radiofrequency and ethanol ablation for treating locally recurrent thyroid cancer: A systematic review and meta-analysis. Thyroid 2016;26:420-8. doi: 10.1089/thy.2015.0545.

55. Kobayashi A, Kuma K, Matsuzuka F, Hirai K, Fukata S, Sugawara M. Thyrotoxicosis after needle aspiration of thyroid cyst. J Clin Endocrinol Metab 1992;75:21-4. doi: 10.1210/jcem.75.1.1619011.

56. Ha EJ, Baek JH, Lee JH, Sung JY, Lee D, Kim JK, et al. Radiofrequency ablation of benign thyroid nodules does not affect thyroid function in patients with previous lobectomy. Thyroid 2013;23:289-93. doi: 10.1089/thy.2012.0171.

57. Brkljacic B, Sucic M, Bozikov V, Hauser M, Hebrang A. Treatment of autonomous and toxic thyroid adenomas by percutaneous ultrasound-guided ethanol injection. Acta Radiol 2001;42:477-81. doi: 10.1034j.1600-0455.2001.420508.x.

58. Shin JH, Baek JH, Ha EJ, Lee JH. Radiofrequency ablation of thyroid nodules: Basic principles and clinical application. Int J Endocrinol 2012;2012:919650. doi: 10.1155/2012/919650.

59. Garberoglio R, Aliberti C, Appetecchia M, Attard M, Boccuzzi G, Boraso F, et al. Radiofrequency ablation for thyroid nodules: Which indications? The first Italian opinion statement. J Ultrasound 2015;18:423-30. doi: 10.1007/s40477-015-0169-y.

60. Baek JH, Jeong HJ, Kim YS, Kwak MS, Lee D. Radiofrequency ablation for an autonomously functioning thyroid nodule. Thyroid 2008;18:675-6. doi: 10.1089/thy.2007.0274.

61. Miller JM, Zafar SU, Karo JJ. The cystic thyroid nodule. Recognition and management. Radiology 1974;110:257-61. doi: 10.1148/110.2.257.

62. Jang SW, Baek JH, Kim JK, Sung JY, Choi H, Lim HK, et al. How to manage the patients with unsatisfactory results after ethanol ablation for thyroid nodules: Role of radiofrequency ablation. Eur J Radiol 2012;81:905-10. doi: 10.1016/j.ejrad.2011.02.039.

63. Baek JH, Lee JH, Valcavi R, Pacella CM, Rhim H, Na DG. Thermal ablation for benign thyroid nodules: Radiofrequency and laser. Korean J Radiol 2011;12:525-40. doi: 10.3348/kjr.2011.12.5.525.

64. Chen F, Tian G, Kong D, Zhong L, Jiang T. Radiofrequency ablation for treatment of benign thyroid nodules: A PRISMA-compliant systematic review and meta-analysis of outcomes. Medicine (Baltimore) 2016;95:e4659. doi: 10.1097/MD.0000000000004659.

65. Ranta A, Salmi J, Sand J. Fatal cervical edema following diagnostic fine needle aspiration. Duodecim 1996;112:2024-5.

66. Roh JL. Intrathyroid hemorrhage and acute upper airway obstruction after fine needle aspiration of the thyroid gland. Laryngoscope 2006;116:154-6. doi: 10.1097/01.mlg.0000187396.18016.d0.

67. Hor T, Lahiri SW. Bilateral thyroid hematomas after fine-needle aspiration causing acute airway obstruction. Thyroid 2008;18:567-9. doi: 10.1089/thy.2007.0363.

68. Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: Conclusions from cross-validations between two centers. Anesthesiology 1999;91:693-700. doi: 10.1097/00000542-199909000-00022.

69. Fujii Y, Saitoh Y, Tanaka H, Toyooka H. Prophylactic antiemetic therapy with granisetron in women undergoing thyroidectomy. Br J Anaesth 1998;81:526-8. doi: 10.1093/bja/81.4.526.

70. Sonner JM, Hynson JM, Clark O, Katz JA. Nausea and vomiting following thyroid and parathyroid surgery. J Clin Anesth 1997;9:398-402. doi: 10.1016/S0952-8180(97)00069-X.

71. Tominaga K, Nakahara T. The twenty-degree reverse-Trendelenburg position decreases the incidence and severity of postoperative nausea and vomiting after thyroid surgery. Anesth Analg 2006;103:1260-3. doi: 10.1213/01.ane.0000240872.08802.f0.

72. Friedrich C, Ulmer C, Rieber F, Kern E, Kohler A, Schymik K, et al. Safety analysis of vagal nerve stimulation for continuous nerve monitoring during thyroid surgery. Laryngoscope 2012;122:1979-87. doi: 10.1002/lary.23411.

73. Apfel CC, Roewer N, Korttila K. How to study postoperative nausea and vomiting. Acta Anaesthesiol Scand 2002;46:921-8. doi: 10.1034/j.1399-6576.2002.460801.x.

74. Pelter MA, Vollmer TA, Blum RL. Seizure-like reaction associated with subcutaneous lidocaine injection. Clin Pharm 1989;8:767-8.
COPYRIGHT 2017 Medknow Publications and Media Pvt. Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Review Article
Author:Wang, Jin-Fen; Wu, Tao; Hu, Kun-Peng; Xu, Wen; Zheng, Bo-Wen; Tong, Ge; Yao, Zhi-Cheng; Liu, Bo; Ren
Publication:Chinese Medical Journal
Article Type:Clinical report
Geographic Code:9CHIN
Date:Jul 27, 2017
Previous Article:Effect of Histone Deacetylase Inhibition on the Expression of Multidrug Resistance-associated Protein 2 in a Human Placental Trophoblast Cell Line.
Next Article:Interventional Radiology in China: Current Status and Future Prospects.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters